The Use of Secretome and Exosomes in Cardiovascular Diseases

Authors

  • Eka Ginanjar Cardiovascular Division, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia – Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Zahra Nuril Anwar Leuwiliang General Hospital, Bogor, Indonesia

Keywords:

exosome, secretomes, cardiovascular diseases

Abstract

Cardiovascular diseases (CVDs) remain a leading cause of morbidity and mortality worldwide. Recent advancements in regenerative medicine have unveiled the promising roles of secretome and exosomes in the treatment of CVDs. In this article, we aim to understand the roles of secretome and exosomes in the cardiovascular system, both in physiological and pathological conditions, and explore the broad applications of secretome and exosomes in mitigating CVD progression. Secretome and exosomes, which play crucial roles in intercellular communication, tissue repair, and immunomodulation, have shown potential in reducing cardiovascular disease progression by inhibiting inflammation, promoting blood vessel growth, and regulating biological mechanisms. Further research is needed to maximize their use in advanced cardiovascular therapy.

References

Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141(9).

Daneshi N, Bahmaie N, Esmaeilzadeh A. Cell-free treatments: a new generation of targeted therapies for treatment of ischemic heart disease. Cell J. 2022;24(7):353–63.

Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012;10(3):244–58.

Nyarko OO, Sucharov CC. The secretome as a biomarker and functional agent in heart failure. The Journal of Cardiovascular Aging. 2023;3(3):27.

Gartz M, Strande JL. Examining the paracrine effects of exosomes in cardiovascular disease and repair. J Am Heart Assoc. 2018;7(11):e007954..

Reiss AB, Ahmed S, Johnson M, Saeedullah U, De Leon J. Exosomes in cardiovascular disease: From mechanism to therapeutic target. Metabolites. 2023;13(4):479.

Zhang Y, Liu Y, Liu H, Tang WH. Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci. 2019;9(1):19.

Nyarko OO, Sucharov CC. The secretome as a biomarker and functional agent in heart failure. The Journal of Cardiovascular Aging. 2023;3(3):27.

Kuwabara Y, Ono K, Horie T, et al. Increased microRNA-1 and microRNA-133a levels in the serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet. 2011;4(4):446–54.

Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341–45.

Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B. 2016;6(4):287–96.

Laura Francés J, Pagiatakis C, Di Mauro V, Climent M. Therapeutic potential of EVs: targeting cardiovascular diseases. Biomedicines. 2023;11(7):1907.

Bang C, Batkai S, Dangwal S, et al. Cardiac fibroblast–derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. Journal of Clinical Investigation. 2014;124(5):2136–46.

Lyu L, Wang H, Li B, et al. A critical role of cardiac fibroblast-derived exosomes in activating the renin angiotensin system in cardiomyocytes. J Mol Cell Cardiol. 2015;89:268–79.

Yamaguchi T, Izumi Y, Nakamura Y, et al. Repeated remote ischemic conditioning attenuates left ventricular remodeling via exosome-mediated intercellular communication in chronic heart failure after myocardial infarction. Int J Cardiol. 2015;178:239–46.

Vicencio JM, Yellon DM, Sivaraman V, et al. Plasma exosomes protect the myocardium from ischemia-reperfusion injury. J Am Coll Cardiol. 2015;65(15):1525–36.

Ibrahim AGE, Cheng K, Marbán E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports. 2014;2(5):606–19.

Bian S, Zhang L, Duan L, Wang X, Min Y, Yu H. Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. J Mol Med. 2014;92(4):387–97.

Barile L, Lionetti V, Cervio E, et al. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res. 2014;103(4):530–41.

Xiao J, Pan Y, Li XH, et al. Cardiac progenitor cell-derived exosomes prevent cardiomyocyte apoptosis through exosomal miR-21 by targeting PDCD4. Cell Death Dis. 2016;7(6):e2277.

Aminzadeh MA, Rogers RG, Fournier M, et al. Exosome-mediated benefits of cell therapy in mouse and human models of Duchenne muscular dystrophy. Stem Cell Reports. 2018;10(3):942–55.

Yu B, Kim HW, Gong M, Wang J, et al. Exosomes secreted from gata-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection. Int J Cardiol. 2015;182:349–60.

Downloads

Published

2025-10-03

How to Cite

Ginanjar, E., & Anwar, Z. N. (2025). The Use of Secretome and Exosomes in Cardiovascular Diseases. Acta Medica Indonesiana, 57(3), 396. Retrieved from http://www.actamedindones.org/index.php/ijim/article/view/2959

Issue

Vol. 57 No. 3 (2025): Acta Medica Indonesiana

Section

REVIEW ARTICLE

License

Copyright (c) 2025 Eka Ginanjar, Zahra Nuril Anwar

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.